



## Remodulin® (treprostinil) – New warnings

- On June 8, 2018, the [FDA approved](#) updates to the *Warnings and Precautions* section of the [Remodulin \(treprostinil\)](#) drug label regarding risk of symptomatic hypotension and risk of bleeding.
- Remodulin is indicated for the treatment of pulmonary arterial hypertension (PAH) and for the treatment of PAH in patients requiring transition from [Flolan® \(epoprostenol\)](#).
- Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
- Remodulin inhibits platelet aggregation and increases the risk of bleeding.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.